{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-021916","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.852833+00:00","generated_at":"2026-05-25T01:21:06.786950+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance","bullets":["Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.","Exclusive global licenses from Columbia University for SPC-15 and SPC-14 (Alzheimer's).","SP-26 (ketamine implant for fibromyalgia) March 2025 data expected; 505(b)(2) pathway planned.","SPC-14 (Alzheimer's) and SPU-16 (multiple sclerosis) in preclinical with 2025 data targets.","Company states sufficient capital resources and no debt to support upcoming catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-021916","json":"https://secwatch.observer/filing/0001213900-25-021916.json","markdown":"https://secwatch.observer/filing/0001213900-25-021916.md","text":"https://secwatch.observer/filing/0001213900-25-021916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/0001213900-25-021916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/ea0233727-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:21:06.786950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}